Edition:
United Kingdom

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

8.30USD
6:18pm GMT
Change (% chg)

$-0.10 (-1.19%)
Prev Close
$8.40
Open
$8.50
Day's High
$8.50
Day's Low
$8.12
Volume
35,708
Avg. Vol
179,239
52-wk High
$17.20
52-wk Low
$7.00

Latest Key Developments (Source: Significant Developments)

Cytokinetics Inc announces negative results from VITALITY-ALS
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Cytokinetics Inc :Cytokinetics announces negative results from VITALITY-ALS.Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints​.No new safety or tolerability findings related to Tirasemtiv were identified in VITALITY-ALS​.Believe that limitations of Tirasemtiv may be addressed with co's next-generation fast skeletal muscle activator, CK-2127107​.Have decided to suspend development of Tirasemtiv​.Limitations of Tirasemtiv may be addressed with co's "next-generation fast" skeletal muscle activator, CK-2127107​.Believe CK-2127107 will be better tolerated, potentially more effective than Tirasemtiv for ALS & look forward to phase 2 results in 2018​.  Full Article

Cytokinetics enters into second amendment to certain loan and security agreement
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Cytokinetics Inc ::Cytokinetics - ‍on Oct 27, entered into second amendment to certain loan and security agreement dated as of October 19, 2015 .Cytokinetics - ‍original loan agreement, as amended by amendment, provides for secured growth capital term loans of up to $50.0 million​.  Full Article

Cytokinetics reports Q3 loss of ‍$0.60/shr​
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Cytokinetics Inc :Cytokinetics, Inc. reports third quarter 2017 financial results.Q3 revenue $6.2 million versus I/B/E/S view $6.5 million.Cytokinetics Inc - qtrly loss per share ‍$0.60​.Cytokinetics Inc- ‍anticipates cash research and development expenses will be in range of $103 million to $107 million for 2017​.  Full Article

Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3
Thursday, 1 Sep 2016 

Cytokinetics Inc : Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3 clinical development . Phase 3 outcomes trial will be conducted by Amgen in collaboration with Cytokinetics .Company and Amgen are also planning a potential exercise performance/cardiac function clinical trial to be conducted by Cytokinetics.  Full Article

Cytokinetics Inc reports q2 2016 financial results
Thursday, 28 Jul 2016 

Cytokinetics Inc : Will not update financial guidance until Q3 earnings due to recent expansion of collaboration with Astellas . Cytokinetics, Inc. reports second quarter 2016 financial results . Q2 loss per share $0.29 . Q2 revenue $5.8 million versus $6.5 million . Q2 revenue view $10.2 million -- Thomson Reuters I/B/E/S . Q2 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S . Expect to make a decision regarding advancement of omecamtiv mecarbil to phase 3 in Q3 of 2016 ."We will not update our financial guidance until our Q3 earnings due to recent expansion of our collaboration with Astellas".  Full Article

Cytokinetics, Astellas announce option right for Tirasemtiv
Wednesday, 27 Jul 2016 

Cytokinetics Inc : Cytokinetics and Astellas announce option right for Tirasemtiv and expansion of global collaboration for CK-2127107 in ALS . Option has potential for more than $100 million in payments associated with exercise of option . To receive $65 million in upfront payments, $30 million in additional sponsored research and development .Companies to extend joint research focused on discovery of skeletal muscle activators through 2017.  Full Article

UPDATE 4-Cytokinetics sinks on abandoning ALS drug after failed trial

Nov 21 Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.